Kwang Kon Koh

List of Publications by Citations

70 papers	3,505 citations	31 h-index	59 g-index
74 ext. papers	3,824 ext. citations	7 avg, IF	4.86 L-index

#	Paper	IF	Citations
70	Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. *Diabetes Care*, **2011**, 34, 1323-8	14.6	459
69	Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. *Journal of the American College of Cardiology*, **2005**, 46, 1978-85	15.1	287
68	Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. *Circulation*, **2004**, 110, 3687-92	16.7	243
67	Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. *Journal of the American College of Cardiology*, **2003**, 42, 905-10	15.1	197
66	Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. *Journal of the American College of Cardiology*, **2005**, 45, 1649-53	15.1	179
65	Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. *Journal of the American College of Cardiology*, **2010**, 55, 1209-1216	15.1	165
64	Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. *Diabetes Care*, **2005**, 28, 1419-24	14.6	159
63	Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. *Hypertension*, **2005**, 45, 1088-93	8.5	126
62	Differential metabolic effects of distinct statins. *Atherosclerosis*, **2011**, 215, 1-8	3.1	103
61	Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. *Diabetes Care*, **2008**, 31, 776-82	14.6	94
60	Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. *Atherosclerosis*, **2009**, 204, 483-90	3.1	93
59	Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. *International Journal of Cardiology*, **2006**, 108, 96-100	3.2	89
58	Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2002**, 22, e19-23	9.4	80
57	Effects of estrogen on the vascular wall: vasomotor function and inflammation. *Cardiovascular Research*, **2002**, 55, 714-26	9.9	77
56	Does reversal of oxidative stress and inflammation provide vascular protection?. *Cardiovascular Research*, **2009**, 81, 649-59	9.9	62
55	Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. *Atherosclerosis*, **2004**, 174, 379-83	3.1	61
54	Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. *International Journal of Cardiology*, **2010**, 140, 73-81	3.2	57

53	Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. *Atherosclerosis*, **2004**, 177, 155-60	3.1	56
52	Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. *American Journal of Cardiology*, **2004**, 93, 1432-5, A10	3	55
51	Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. *Diabetes Care*, **2006**, 29, 195-201	14.6	54
50	Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction. *Atherosclerosis*, **2010**, 209, 307-13	3.1	45
49	Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients. *International Journal of Cardiology*, **2013**, 166, 509-15	3.2	44
48	Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2003**, 23, 1889-94	9.4	44
47	Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. *Atherosclerosis*, **2012**, 220, 537-44	3.1	41
46	Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. *European Heart Journal*, **2007**, 28, 1440-7	9.5	41
45	Simvastatin combined with ramipril treatment in hypercholesterolemic patients. *Hypertension*, **2004**, 44, 180-5	8.5	41
44	Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials?. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2004**, 24, 1171-9	9.4	41
43	Vascular effects of diet and statin in hypercholesterolemic patients. *International Journal of Cardiology*, **2004**, 95, 185-91	3.2	40
42	Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in nondiabetic patients with hypertension. *Diabetes Care*, **2007**, 30, 1605-7	14.6	37
41	Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. *International Journal of Cardiology*, **2008**, 124, 149-59	3.2	34
40	Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. *International Journal of Cardiology*, **2009**, 133, 23-31	3.2	31
39	Are statins effective for simultaneously treating dyslipidemias and hypertension?. *Atherosclerosis*, **2008**, 196, 1-8	3.1	30
38	Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study. *European Heart Journal*, **2005**, 26, 1362-8	9.5	28
37	Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. *International Journal of Cardiology*, **2004**, 97, 239-44	3.2	28
36	Effects of continuous combined hormone replacement therapy on inflammation in hypertensive and/or overweight postmenopausal women. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2002**, 22, 1459-64	9.4	28

35	Controversies regarding hormone therapy: Insights from inflammation and hemostasis. *Cardiovascular Research*, **2006**, 70, 22-30	9.9	27
34	Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy?. *International Journal of Cardiology*, **2003**, 87, 1-8	3.2	25
33	Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. *International Journal of Cardiology*, **2011**, 146, 319-25	3.2	23
32	Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. *Atherosclerosis*, **2007**, 194, 230-7	3.1	20
31	How to balance cardiorenometabolic benefits and risks of statins. *Atherosclerosis*, **2014**, 235, 644-8	3.1	19
30	Vascular and metabolic effects of candesartan: insights from therapeutic interventions. *Journal of Hypertension*, **2006**, 24, S31-8	1.9	18
29	Impact of Longitudinal Changes in Metabolic Syndrome Status over 2 Years on 10-Year Incident Diabetes Mellitus. *Diabetes and Metabolism Journal*, **2019**, 43, 530-538	5	14
28	Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women. *International Journal of Hematology*, **2002**, 76 Suppl 2, 44-6	2.3	12
27	Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study. *Atherosclerosis*, **2004**, 177, 147-53	3.1	12
26	Rosuvastatin treatment improves arterial stiffness with lowering blood pressure in healthy hypercholesterolemic patients. *International Journal of Cardiology*, **2014**, 176, 1284-7	3.2	11
25	Vascular effects of step I diet in hypercholesterolemic patients with coronary artery disease. *American Journal of Cardiology*, **2003**, 92, 708-10	3	10
24	Lipoprotein(a) and Cardiovascular Diseases - Revisited. *Circulation Journal*, **2020**, 84, 867-874	2.9	9
23	Cardiovascular effects of omega-3 fatty acids: Hope or hype?. *Atherosclerosis*, **2021**, 322, 15-23	3.1	8
22	Effects of Simvastatin Alone or Combined With Ramipril on Nitric Oxide Bioactivity and Inflammation Markers in Hypercholesterolemic Patients. *Sunhwan□gi*, **2003**, 33, 1053		7
21	The role of insulin resistance and metabolic risk factors on culprit coronary plaque. *International Journal of Cardiology*, **2015**, 190, 56-62	3.2	6
20	Comparative effects of diet and simvastatin on markers of thrombogenicity in patients with coronary artery disease. *American Journal of Cardiology*, **2003**, 91, 1231-4	3	6
19	Metabolic Syndrome Fact Sheet 2021: Executive Report. *Cardiometabolic Syndrome Journal*, **2021**, 1, 125		5
18	New Trends in Dyslipidemia Treatment. *Circulation Journal*, **2021**, 85, 759-768	2.9	4

List of Publications

17	Repeated Aborted Sudden Cardiac Death with Long QT Syndrome in a Patient with Anomalous Origin of the Right Coronary Artery from the Left Coronary Cusp. *Korean Circulation Journal*, **2013**, 43, 830-3	2.2	2
16	Efficacy of Thrombosuction using the Export Aspiration Catheter before Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. *Korean Circulation Journal*, **2005**, 35, 172	2.2	2
15	Letter by Koh Regarding Articles, "Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China)" and "Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population". *Circulation*, **2017**, 135, e818-e819	16.7	1
14	Letter by Koh Regarding Article, "Dipeptidyl Peptidase-4 Induces Aortic Valve Calcification by Inhibiting Insulin-Like Growth Factor-1 Signaling in Valvular Interstitial Cells". *Circulation*, **2017**, 136, 1668-1669	16.7	1
13	Images in cardiovascular medicine. Neovascularization from coronary artery leaking to fungus ball in the lung. *Circulation*, **2006**, 114, e551-2	16.7	1
12	Which biomarker to use, when to start, and how to improve adherence for reducing atherosclerotic cardiovascular disease risk?. *European Heart Journal*, **2021**, 42, 1808	9.5	1
11	Letter by Koh Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)". *Circulation*, **2018**, 137, 639-640	16.7	
10	Letter by Koh Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". *Circulation*, **2018**, 137, 2660-2661	16.7	
9	Clinical Significance of Left Ventricular Torsional Parameters during Supine Bicycle Cardiopulmonary Exercise Echocardiography. *Journal of Cardiovascular Imaging*, **2009**, 17, 2	0	
8	Evaluation of Sympathetic Reinnervation Using 123I-MIBG Scintigraphy in Cardiac Transplants. *Sunhwan□gi*, **2003**, 33, 909		
7	Long-term Outcomes of Primary Stenting in Acute Myocaridal Infarction. *Sunhwan□gi*, **2001**, 31, 742		
6	Letter by Koh Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)". *Circulation*, **2019**, 139, 416-417	16.7	
5	Letter by Koh Regarding Article, "PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS)". *Circulation*, **2018**, 138, 1283-1284	16.7	
4	Letter by Koh Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease". *Circulation*, **2018**, 138, 846-847	16.7	
3	Letter by Koh Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". *Circulation*, **2018**, 138, 1914-1915	16.7	
2	Letter by Koh Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up". *Circulation*, **2018**, 137, 2417-2418	16.7	
1	Left Atrial Thrombus and Multiple Infarcts. *Cardiometabolic Syndrome Journal*, **2021**, 1, 114		